Advertisement

Monitoring neuroprotection and restorative therapies in Parkinson’s disease with PET

  • D. J. Brooks
Conference paper

Summary

In this article the role of functional imaging (PET and SPECT) as a surrogate marker for following the progression of Parkinson’s disease (PD) is discussed. The potential value of PET and SPECT for assessing the efficacy of putative neuroprotective agents in PD is considered and a review of 18F-dopa PET findings in transplantation trials involving implantation of human and procine fetal mesencephalic tissue is presented. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective and restorative approaches to PD.

Keywords

Positron Emission Tomography Multiple System Atrophy Restorative Therapy Dopa Positron Emission Tomography Nigral Cell Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K (1997) Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fischer 344 and Sprague-Dawley donors. Cell Transplant 6: 309-315PubMedCrossRefGoogle Scholar
  2. Banati RB, Goerres GW, Brooks DJ et al (1999a) PK11195 positron emission tomography imaging of activated microglia in Rasmussen’s encephalitis. Neurology 53: 2199-2203PubMedCrossRefGoogle Scholar
  3. Banati R, Cagnin A, Myers R et al (1999b) In vivo detection of activated microglia by ["C]PK11195-PET indicates involvement of the globus pallidum in idiopathic Parkinson’s disease. Parkinsonism Relat Disord 5: S56 (abstr)Google Scholar
  4. Brundin P, Pogarel O, Hagell P et al (2000) Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain (in press)Google Scholar
  5. Ellias SA, Palmer EP, Kott HS et al (1998) Transplantation of fetal porcine ventral mesencephalic cells for treatment of Parkinson’s disease: One year safety and efficacy results. Neurology 50 Suppl 4: A80CrossRefGoogle Scholar
  6. Fahn S, Elton RL, and members of the UPDRS development committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M et al (eds) Recent developments in Parkinson’s disease. Macmillan, New York, 153-163Google Scholar
  7. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain 114: 2283-2301PubMedCrossRefGoogle Scholar
  8. Freed CR, Breeze RE, Rosenberg NL et al (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Engl J Med 327: 1549-1555PubMedCrossRefGoogle Scholar
  9. Freeman TB, Olanow CW, Hauser RA et al (1995) Bilateral fetal nigral transplantion into the post-commisural putamen as a treatment for Parkinson’s disease: six months follow-up. Ann Neurol 38: 379-388PubMedCrossRefGoogle Scholar
  10. Hagell P, Schrag AE, Piccini P et al (1999) Sequential bilateral transplantation in Parkinson’s disease: Effects of the second graft. Brain 122: 1121-1132PubMedCrossRefGoogle Scholar
  11. Hauser RA, Freeman TB, Snow BJ et al (1999) Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56: 179-187PubMedCrossRefGoogle Scholar
  12. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992a) The accuracy of the clinical diagnosis of Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184PubMedCrossRefGoogle Scholar
  13. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992b) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathological study. Neurology 42: 1142-1146PubMedCrossRefGoogle Scholar
  14. Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, 33-65Google Scholar
  15. Kordower JH, Freeman TB, Snow BJ et al (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 332: 1118-1124PubMedCrossRefGoogle Scholar
  16. Kordower JH, Freeman TB, Chen EY et al (1998) Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Disord 13: 383-393PubMedCrossRefGoogle Scholar
  17. Kuwabara H, Cumming P, Reith J et al (1993) Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[’8F]fluorodopa and positron emission tomography: Error analysis and application to normal subjects. J Cereb Blood Flow Metab 13: 43-56PubMedCrossRefGoogle Scholar
  18. Lang AE, Benabid AL, Koller WC et al (1995) The Core Assessment Program for intracerebral transplantation. Mov Disord 10: 527-528PubMedCrossRefGoogle Scholar
  19. Langston JW, Widner H, Goetz CG et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7: 2-13PubMedCrossRefGoogle Scholar
  20. Leber P (1997) Slowing the progression of Alzheimer disease: Methodologic issues. Alzheimer Dis Assoc Disord 11 Suppl 5: S10-S20Google Scholar
  21. Louis DE, Tang MX, Cote L, Alfaro B, Mejia H, Marder KM (1999) Progression of parkinsonian signs in Parkinson’s disease. Arch Neurol 56: 334-337PubMedCrossRefGoogle Scholar
  22. Marek KL, Innis RB, Seibyl J (1998) Assessment of Parkinson’s disease progression with 3-CIT and SPECT imaging. Mov Disord 13 Suppl 2: 238 (abstr)Google Scholar
  23. Martinez-Martin P, Gil-Nagel A, Gracia LM et al (1994) Unified Parkinson’s disease rating scale: characteristics and structure. Mov Disord 9: 76-83PubMedCrossRefGoogle Scholar
  24. Morrish PK, Sawle GV, Brooks DJ (1995) Clinical and [18F]dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 59: 597-600PubMedCrossRefGoogle Scholar
  25. Morrish PK, Sawle GV, Brooks DJ (1996) An [18F]dopa PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119: 585-591PubMedCrossRefGoogle Scholar
  26. Morrish PK, Rakshi JS, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64: 314-319PubMedCrossRefGoogle Scholar
  27. Nurmi EM, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Rinne JO (1999) The rate of progression in Parkinson’s disease: A [18F]Dopa PET study. Neurology 52 Suppl 2: A91 (abstr)Google Scholar
  28. Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson’s disease. Ann Neurol 44 Suppl 1: S167-S174Google Scholar
  29. Otsuka M, Ichiya Y, Kuwabara Y et al (1996) Differences in the reduced 18F-dopa uptakes of the caudate and the putamen in Parkinson’s disease: Correlations with the three main symptoms. J Neurol Sci 136: 169-173PubMedCrossRefGoogle Scholar
  30. Pate BD, Kawamata T, Yamada T et al (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34: 331-338PubMedCrossRefGoogle Scholar
  31. Piccini P, Brooks DJ, Bjorklund A et al (1999) Dopamine release from nigral transplants visualised in vivo in a Parkinson’s patient. Nat Neurosci 2: 1137-1140PubMedCrossRefGoogle Scholar
  32. Rakshi JS, Bailey DL, Morrish PK, Brooks DJ (1996) Implementation of 3D acquisition, reconstruction, and analysis of dynamic [18F] Fluorodopa studies. In: Myers R, Cunningham V, Bailey D, Jones T (eds), Quantification of brain function using PET. Academic Press, San Diego, 82-87CrossRefGoogle Scholar
  33. Remy P, Samson Y, Hantraye P et al (1995) Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 38: 580-588PubMedCrossRefGoogle Scholar
  34. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS (1990) Striatal function in normal aging: Implications for Parkinson’s disease. Ann Neurol 28: 799-804.PubMedCrossRefGoogle Scholar
  35. Shoulson I, The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364-1371CrossRefGoogle Scholar
  36. Snow BJ, Tooyama I, McGeer EG et al (1993) Human positron emission tomographic I18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324-330PubMedCrossRefGoogle Scholar
  37. Turjanski N, Lees AJ, Brooks DJ (1999) Striatal dopaminergic receptor dysfunction in patients with restless legs syndrome: 18F-dopa and "C-raclopride PET studies. Neurology 52: 932-937PubMedCrossRefGoogle Scholar
  38. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36: 759-764PubMedCrossRefGoogle Scholar
  39. Ward CD (1994) Does selegiline delay the progression of Parkinson’s disease? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57: 217-220PubMedCrossRefGoogle Scholar
  40. Widner H, Tetrud J, Rehncrona S et al (1992) Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP). N Engl J Med 327: 1556-1563PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • D. J. Brooks
    • 1
  1. 1.MRC Clinical Sciences Centre, Imperial College School of MedicineHammersmith HospitalLondonUK

Personalised recommendations